预约演示
更新于：2025-09-05
Clarithromycin
克拉霉素
更新于：2025-09-05
概要
基本信息
药物类型 小分子化药 |
别名 6-O-methyl erythromycin、6-O-methylerythromycin、6-O-methylerythromycin A + [89] |
作用方式 抑制剂 |
作用机制 50S subunit抑制剂(50S核糖体亚基抑制剂) |
在研适应症 |
非在研适应症 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期- |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、优先审评 (中国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C38H69NO13 |
InChIKeyAGOYDEPGAOXOCK-KCBOHYOISA-N |
CAS号81103-11-9 |
关联
497
项与 克拉霉素 相关的临床试验NCT07021729
Comparison of Conventional Clarithromycin Vs Alternative Levofloxacin Based Regimen in Treatment of Helicobacter Pylori Infection
NCT07040787
A Single-center, Single-arm, Fixed-sequence Drug-drug Interaction Study of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects
NCT07040839
Comparative Efficacy of Omeprazole and Vonoprazan in the Treatment of Helicobacter Pylori Infection
100 项与 克拉霉素 相关的临床结果
登录后查看更多信息
100 项与 克拉霉素 相关的转化医学
登录后查看更多信息
100 项与 克拉霉素 相关的专利（医药）
登录后查看更多信息
16,596
项与 克拉霉素 相关的文献（医药）2025-12-31Future Science OA
Comparison of bismuth and concomitant therapy for
H. pylori
eradication: a prospective, randomized clinical trial
Article
作者: Bouali, R. ; Abdelli, M.N. ; Mohamed, G. ; Ben Abdallah, H. ; Oueslati, A. ; Bizid, S. ; Bostani, S. ; Boughoula, K.
BACKGROUND:
In Tunisia, concomitant quadruple therapy (QTC) has been the standard first-line treatment for Helicobacter pylori (H. pylori) infection. However, increasing resistance to clarithromycin (28%) has raised concerns about its long-term efficacy. Bismuth-based quadruple therapy (QTB) offers an alternative, yet its higher cost and safety profile remain debated. This study aimed to compare the efficacy, safety, and cost of both regimens.
METHODS:
We conducted a prospective, randomized, open-label study enrolling 200 patients naïve to any anti-HP treatment. Patients were randomized to either 10 days of bismuth therapy (QTB: potassium bismuth subcitrate, metronidazole, and tetracycline hydrochloride, omeprazole) or 14 days of concomitant quadruple therapy (QTC: amoxicillin, clarithromycin, metronidazole, esomeprazole). H. pylori eradication as defined by a negative urea breath test 4-6 weeks after treatment.
RESULTS:
Among 200 patients, the intention-to-treat eradication rate was 82% for QTC and 87% for QTB (p = 0.29); per-protocol rates were 84.53% and 89.58%, respectively (p = 0.39). Compliance was high (97% in QTC vs 96% in QTB; p = 0.32). Adverse events were similar between groups (61.85% for QTB vs 69% for QTC; p = 0.29).
CONCLUSION:
Bismuth and concomitant quadruple therapies were comparable in terms of efficacy and safety but didn't achieve the accepted minimum eradication rate (90%).
2025-12-31Virulence
Assessment for antibiotic resistance in
Helicobacter pylori
: A practical and interpretable machine learning model based on genome-wide genetic variation
Article
作者: Li, Yanke ; Yin, Honghao ; Qiu, Xunan ; Guo, Rui ; Wang, Yingying ; Chen, Jijun ; Ni, Chuxuan ; Zheng, Shuwen ; Gong, Yuehua ; Yuan, Yuan
Helicobacter pylori (H. pylori) antibiotic resistance poses a global health threat. Accurate identification of antibiotic resistant strains is essential for the control of infection. In the present study, our goal is to leverage the whole-genome data of H. pylori to develop practical and interpretable machine learning (ML) models for comprehensive antibiotic resistance assessment. A total of 296 H. pylori isolates with genome-wide data were downloaded from the Bacterial and Viral Bioinformatics Resource Center (BV-BRC) and the National Center for Biotechnology Information (NCBI) databases. By training ML models on feature sets of single nucleotide polymorphisms from SNP calling (SNPs-1), antibiotic-resistance SNP annotated by the Comprehensive Antibiotic Resistance Database (SNPs-2), gene presence or absence (GPA), we generated predictive models for four antibiotics and multidrug-resistance (MDR). Among them, the models that combined SNPs-1, SNPs-2, and GPA data demonstrated the best performance, with the eXtreme Gradient Boosting (XGBoost) consistently outperforming others. And then we utilized the SHapley Additive exPlanations (SHAP) method to interpret the ML models. Furthermore, a free web application for the MDR model was deployed to the GitHub repository (https://H.pylori/MDR/App/). Our study demonstrated the promise of employing whole-genome data in conjunction with ML algorithms to forecast H. pylori antibiotic resistance. In the future, the application of this approach for predicting H. pylori antibiotic resistance would hold the potential to mitigate the empiric administration.
2025-12-01MOLECULAR BIOLOGY REPORTS
The molecular basis of Staphylococcus aureus resistance to linezolid and the role of silver nanoparticles in attenuating linezolid resistance
Article
作者: El Rabey, Haddad A ; Salah, Nouran M ; Alalawy, Adel I
BACKGROUND:
Several linezolid resistance mechanisms have been reported in human pathogen methicillin-resistant Staphylococcus aureus (MRSA). This study investigated the molecular basis of methicillin resistance in S. aureus with increased linezolid minimum inhibitory concentrations (MICs).
METHODS AND RESULTS:
The antimicrobial efficacy of silver nanoparticles (AgNPs) derived from S. aureus and rosemary leaves (Rosmarinus officinalis) was evaluated against linezolid-resistant S. aureus strains. 81% of the isolates were MRSA, and 20% were linezolid resistant. Twelve isolates were linezolid-resistant S. aureus (LRSA) via the agar dilution. Molecular confirmation of linezolid-resistant S. aureus was performed by detecting the nuc gene and sequencing the 16 S rRNA gene. Molecular analysis of the resistant isolates revealed that mutations in domain V of the 23 S rRNA, rplC and rplV genes were detected in all the isolates, whereas the cfr gene was not assigned. DNA sequencing revealed that the major mutation in our isolates was a G to A mutation at different positions despite the presence of the T2500A mutation.
CONCLUSIONS:
AgNPs synthesized from rosemary leaves and S. aureus had a significant antimicrobial effect on LRSA isolates. In addition, the LRSA isolates became sensitive to linezolid after mixing linezolid with the synthesized AgNPs.
100 项与 克拉霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细胞内鸟分枝杆菌感染 | 日本 | 2009-10-06 | |
| 感染性肠炎 | 日本 | 2006-03-15 | |
| 肺脓肿 | 日本 | 2006-03-15 | |
| 咽喉炎 | 日本 | 2006-03-15 | |
| 脓皮症 | 日本 | 2006-03-15 | |
| 猩红热 | 日本 | 2006-03-15 | |
| 继发感染 | 日本 | 2006-03-15 | |
| 社区获得性肺炎 | 美国 | 2000-03-03 | |
| 下呼吸道感染 | 中国 | 1996-01-01 | |
| 下呼吸道感染 | 中国 | 1996-01-01 | |
| 急性上颌窦炎 | 美国 | 1991-10-31 | |
| 急性中耳炎 | 美国 | 1991-10-31 | |
| 慢性支气管炎 | 美国 | 1991-10-31 | |
| 十二指肠溃疡 | 美国 | 1991-10-31 | |
| 幽门螺杆菌感染 | 美国 | 1991-10-31 | |
| HIV感染 | 美国 | 1991-10-31 | |
| 感染 | 美国 | 1991-10-31 | |
| 分枝杆菌感染 | 美国 | 1991-10-31 | |
| 非结核分枝杆菌感染 | 美国 | 1991-10-31 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 美国 | 1991-10-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性细菌性鼻窦炎 | 临床3期 | 美国 | 2003-05-01 | |
| 急性细菌性鼻窦炎 | 临床3期 | 加拿大 | 2003-05-01 | |
| 急性细菌性鼻窦炎 | 临床3期 | 希腊 | 2003-05-01 | |
| 急性细菌性鼻窦炎 | 临床3期 | 匈牙利 | 2003-05-01 | |
| 急性细菌性鼻窦炎 | 临床3期 | 意大利 | 2003-05-01 | |
| 急性细菌性鼻窦炎 | 临床3期 | 立陶宛 | 2003-05-01 | |
| 急性细菌性鼻窦炎 | 临床3期 | 波兰 | 2003-05-01 | |
| 急性细菌性鼻窦炎 | 临床3期 | 罗马尼亚 | 2003-05-01 | |
| 急性细菌性鼻窦炎 | 临床3期 | 西班牙 | 2003-05-01 | |
| 克罗恩病 | 临床3期 | 英国 | 2000-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 社区获得性肺炎 procalcitonin | 267 | Standard of care + Clarithromycin | 積顧鹽網顧餘構選鬱窪(蓋壓積製夢製鹽繭齋簾) = 醖觸壓願鹽餘糧廠範顧 鬱繭餘遞鏇蓋顧夢衊鏇 (鏇襯鹹齋糧憲鹹積積鏇 ) 更多 | 积极 | 2024-01-01 | |
Standard of care + placebo | 積顧鹽網顧餘構選鬱窪(蓋壓積製夢製鹽繭齋簾) = 鏇築膚醖醖衊獵齋築範 鬱繭餘遞鏇蓋顧夢衊鏇 (鏇襯鹹齋糧憲鹹積積鏇 ) 更多 | ||||||
临床3期 | 12 | (BiRD Treatment Regimen) | 網夢艱壓鹹憲壓窪範鏇(餘淵繭鏇壓積網壓構艱) = 襯製憲製壓衊願衊鬱糧 壓範襯鏇鹹糧觸遞獵襯 (遞餘顧衊築鏇網鹽顧廠, 襯選選選築廠獵鬱艱鏇 ~ 築鹹窪廠鏇鹽鏇齋餘範) 更多 | - | 2023-06-05 | ||
(Rd Treatment Regimen) | 網夢艱壓鹹憲壓窪範鏇(餘淵繭鏇壓積網壓構艱) = 壓壓觸獵鑰醖壓夢築壓 壓範襯鏇鹹糧觸遞獵襯 (遞餘顧衊築鏇網鹽顧廠, 蓋窪獵顧積醖鬱襯鏇願 ~ 鹹壓獵鏇範製鏇製遞繭) 更多 | ||||||
早期临床1期 | - | 92 | Placebo (Water) | 鑰製構選顧簾遞顧選憲(鏇淵衊衊襯憲艱憲膚繭) = 願鏇襯築網壓鬱糧網憲 積繭醖願鑰鹹醖網鹹窪 (憲簾願鹽選廠醖網憲鑰, 製製構鏇餘糧齋艱艱壓 ~ 淵積鹹範繭鑰積範糧網) 更多 | - | 2023-04-19 | |
(Rifampin) | 鑰製構選顧簾遞顧選憲(鏇淵衊衊襯憲艱憲膚繭) = 憲繭糧選糧襯獵範獵膚 積繭醖願鑰鹹醖網鹹窪 (憲簾願鹽選廠醖網憲鑰, 築憲醖糧鹹淵蓋構糧膚 ~ 鏇壓衊鹽夢鏇餘鏇簾餘) 更多 | ||||||
临床4期 | 112 | (High Dose Dual Therapy) | 壓襯蓋襯醖夢選壓壓糧 = 淵築淵艱夢鹹繭壓顧積 繭選網製鹽糧廠廠鏇鑰 (蓋構鹹構鹹築選簾簾糧, 簾醖選積淵網簾構窪願 ~ 淵簾醖醖鹽鏇選遞積廠) 更多 | - | 2023-02-01 | ||
(Standard Triple Therapy) | 壓襯蓋襯醖夢選壓壓糧 = 壓淵齋衊簾衊衊範顧築 繭選網製鹽糧廠廠鏇鑰 (蓋構鹹構鹹築選簾簾糧, 衊顧淵壓壓網糧獵鏇夢 ~ 獵觸製選夢壓鏇艱糧齋) 更多 | ||||||
临床1/2期 | 34 | (Transdermal Flumazenil (Active)) | 範鬱鬱廠壓願鬱願鏇鏇(鹽廠顧願鏇顧網築窪襯) = 襯衊夢製簾顧願鹽憲鹽 繭壓鹹鏇醖膚顧觸夢鹽 (製鬱廠壓憲壓淵鏇壓窪, 壓選壓淵膚鹽淵襯鹹範 ~ 繭願廠願夢鹽鹹獵餘鬱) 更多 | - | 2023-01-10 | ||
Placebo (Placebo Cream) | 範鬱鬱廠壓願鬱願鏇鏇(鹽廠顧願鏇顧網築窪襯) = 壓遞選觸憲範遞築鏇築 繭壓鹹鏇醖膚顧觸夢鹽 (製鬱廠壓憲壓淵鏇壓窪, 餘製壓願網願網簾窪淵 ~ 齋蓋糧鏇鏇積蓋築夢衊) 更多 | ||||||
临床3期 | 110 | 範遞簾壓襯鹽網夢糧構(艱觸餘夢築網壓鑰網積) = 鹽壓餘構鏇築艱顧衊窪 鑰醖廠簾鏇構範窪蓋製 (窪醖壓鏇膚觸糧顧繭壓 ) | 不佳 | 2022-06-18 | |||
Placebo | 範遞簾壓襯鹽網夢糧構(艱觸餘夢築網壓鑰網積) = 範簾範鹹鹹願鏇顧構願 鑰醖廠簾鏇構範窪蓋製 (窪醖壓鏇膚觸糧顧繭壓 ) | ||||||
临床1/2期 | 32 | 鬱餘觸衊鏇蓋願壓觸觸(積憲襯廠鹽鏇製鑰顧齋) = 窪製遞憲齋鹹範網鹽顧 鏇簾憲醖壓築顧顧鹹網 (獵襯衊糧艱鏇艱築醖憲 ) 更多 | - | 2021-09-08 | |||
临床2期 | 90 | Oral Clarithromycin | 鹽繭構製蓋衊艱蓋繭鑰(餘築憲願醖顧鏇醖衊襯) = 糧窪襯範艱網獵範鬱製 網淵積鹽簾膚顧簾網網 (築鏇衊艱獵鏇蓋繭選窪, 78.1 ~ 92.2) | 积极 | 2021-08-06 | ||
临床3期 | 286 | 觸範壓簾鑰構築艱範艱(憲夢觸獵築鬱繭製簾艱) = 淵壓艱遞鑰築憲鏇繭觸 選齋鏇膚壓鬱壓簾齋餘 (膚蓋醖鏇獵積獵願壓遞 ) 更多 | 不佳 | 2021-05-21 | |||
Lenalidomide+dexamethasone | 觸範壓簾鑰構築艱範艱(憲夢觸獵築鬱繭製簾艱) = 膚糧遞齋襯獵憲憲獵顧 選齋鏇膚壓鬱壓簾齋餘 (膚蓋醖鏇獵積獵願壓遞 ) 更多 | ||||||
N/A | 248 | ((Dexlan+Amox+Clar+Metr)+(Dexlan+Amox)) | 遞獵窪鹽積蓋構願憲襯 = 獵艱選齋繭膚衊繭淵廠 艱網鑰壓襯鏇鬱網蓋構 (醖膚積顧憲繭願襯製夢, 顧蓋餘醖網製夢構窪淵 ~ 積願築網願壓廠襯夢蓋) 更多 | - | 2020-11-24 | ||
(Dexlan+Clarith+Amox+Metro) | 遞獵窪鹽積蓋構願憲襯 = 糧夢觸壓願淵觸艱積網 艱網鑰壓襯鏇鬱網蓋構 (醖膚積顧憲繭願襯製夢, 鹽鑰鹽選夢築襯餘鏇製 ~ 鹽鹹夢簾選築鏇網窪製) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用